Obstructive hypertrophic cardiomyopathy: a review of new therapies

Nandini Mehra,Adel Hajj Ali,Milind Y Desai
DOI: https://doi.org/10.2217/fca-2023-0056
Abstract:Hypertrophic cardiomyopathy (HCM) is a phenotypically heterogeneous disease with a genetic basis and variable penetrance. The hallmarks of HCM include dynamic left ventricular outflow tract obstruction, typically caused by asymmetric septal hypertrophy. However, abnormal papillary muscle placement, abnormal mitral valve and subvalvular apparatus and apical hypertrophic forms have also been described. Typical medical treatment has been stagnant for decades, although there have been significant advances in surgical treatment of patients with obstructive HCM. Herein, we describe a new class of drugs targeting the specific pathophysiology of HCM.
What problem does this paper attempt to address?